PMA device
CyPass Micro-Stent
Alcon Research, Ltd. · Intraocular Pressure Lowering Implant (OGO, Class III) · First FDA decision Aug 18, 2017, newest Apr 9, 2020Glaucoma
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
7
Naming "CyPass Micro-Stent"
MAUDE reports
4
Brand "CyPass Micro-Stent", since 2015
PubMed studies
40
Mentioning "CyPass Micro-Stent"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing CyPass Micro-Stent
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- CyPass Micro-StentPMA supplement
P150037-S014 · Decided Apr 9, 2020 · 111 days after receipt · Normal 180 Day Track No User Fee
Device type: Intraocular pressure lowering implant (OGO) · Ophthalmology
- CyPass Micro-StentPMA supplement
P150037-S006 · Decided Aug 18, 2017 · 77 days after receipt · Normal 180 Day Track No User Fee
Device type: Intraocular pressure lowering implant (OGO) · Ophthalmology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Implantable Pulmonary Artery Pressure Sensors for Heart Failure ManagementNational determinationOn the books20.36Updated Oct 6, 2026
- Implantable Pulmonary Artery Pressure Sensors for Heart Failure ManagementNational analysisReview closedCAG-00466NUpdated Sep 18, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "CyPass Micro-Stent", any status and sponsor, newest update first.
Alcon ResearchNot on our public-company list
NCT04629521 · 54 participants · Start Dec 21, 2020 · Primary completion Apr 5, 2023
Device: CyPass Micro-Stent · For: Primary Open Angle Glaucoma; Cataract
Sites: Glendale, Arizona; Orange, California; Fort Collins, Colorado · 12 sites in all
- Post Approval Study of the CyPass SystemTerminated
Alcon ResearchNot on our public-company list
NCT03273907 · 79 participants · Start Oct 12, 2017 · Primary completion Aug 31, 2021
Device: CyPass Micro-Stent implanted with CyPass 241-S applier · For: Primary Open-angle Glaucoma; Cataract
Sites: Phoenix, Arizona; Orange, California; Fort Collins, Colorado · 20 sites in all
- A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS TrialPivotal-lookingCompleted
Alcon ResearchNot on our public-company list
NCT02700984 · 282 participants · Start Mar 30, 2016 · Primary completion Apr 18, 2018
Device: CyPass Micro-Stent · For: Primary Open Angle Glaucoma (POAG)
Sites: Glendale, Arizona; Fayetteville, Arkansas; La Jolla, California · 22 sites in all
4 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "CyPass Micro-Stent", and for the whole product code for context.
This brand
4 reports: 0 malfunction, 4 injury, 0 death
Whole product code OGO
2,634 reports: 667 malfunction, 1,967 injury, 0 death
Newest reports for this brand
- CYPASS MICRO-STENTInjury
MW5094625 · Received May 20, 2020 · Event dated Nov 14, 2017 · 1 other device named on this report
Device type: Intraocular Pressure Lowering Implant (OGO)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Blurred Vision
- CYPASS MICRO-STENTInjury
MW5083828 · Received Feb 7, 2019 · Event dated May 5, 2018
Device type: Intraocular Pressure Lowering Implant (OGO)
Device problem as coded: Nonstandard Device
Patient problem as coded: Scar Tissue; Loss of Vision
- CYPASS MICRO STENTInjury
MW5081126 · Received Nov 6, 2018 · Event dated Aug 8, 2018
Device type: Intraocular Pressure Lowering Implant (OGO)
Device problem as coded: Improper or Incorrect Procedure or Method
Patient problem as coded: Corneal Abrasion; Emotional Changes; Pain; Blurred Vision
1 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0185-2019 · Started Aug 28, 2018 · Posted by FDA Oct 23, 2018
Reason given: Analysis of the completed dataset from the COMPASS-XT long-term study showed that the CyPass Micro-Stent group experienced statistically significant endothelial cell loss (ECL) compared to the group who underwent cataract surgery alone.
Cause as FDA categorized it: Device Design · Device type: Intraocular Pressure Lowering Implant (OGO)
Z-0186-2019 · Started Aug 28, 2018 · Posted by FDA Oct 23, 2018
Reason given: Analysis of the completed dataset from the COMPASS-XT long-term study showed that the CyPass Micro-Stent group experienced statistically significant endothelial cell loss (ECL) compared to the group who underwent cataract surgery alone.
Cause as FDA categorized it: Device Design · Device type: Intraocular Pressure Lowering Implant (OGO)
Z-0187-2019 · Started Aug 28, 2018 · Posted by FDA Oct 23, 2018
Reason given: Analysis of the completed dataset from the COMPASS-XT long-term study showed that the CyPass Micro-Stent group experienced statistically significant endothelial cell loss (ECL) compared to the group who underwent cataract surgery alone.
Cause as FDA categorized it: Device Design · Device type: Intraocular Pressure Lowering Implant (OGO)
1 more recall records with a free account
Published research
The most relevant PubMed records for "CyPass Micro-Stent"[tiab]. The summary above synthesizes these.
- Complications after CyPass® Micro-Stent explantation: a case series.
Habbe KJ, Kohlhaas M, Fili S · Int Ophthalmol · 2024
- Suprachoroidal shunts.
Vinod K · Curr Opin Ophthalmol · 2018Review
- Foreign body reaction after CyPass® Micro-Stent implantation: a case series.
Habbe KJ, Kohlhaas M, Langwieder C, et al. · Graefes Arch Clin Exp Ophthalmol · 2023
- CyPass® Micro-Stent Safety and Efficacy at One Year: What Have We Learned?
Gabbay IE, Ruben S · J Curr Glaucoma Pract · 2019
- Delayed bilateral hypertensive crisis with CyPass Micro-stent - The highs and lows.
McCartney M, Phagura RS · Am J Ophthalmol Case Rep · 2020Case Reports
- Corneal endothelial safety profile in minimally invasive glaucoma surgery.
Ahmed IIK, Sheybani A, De Francesco T, et al. · J Cataract Refract Surg · 2024Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Chronic Granulomatous Inflammation after CyPass® Implantation.
Schoelles KJ, Anton A, Auw-Haedrich C · Ocul Oncol Pathol · 2020Case Reports
- Clinical investigation of new glaucoma procedures.
Vinod K, Gedde SJ · Curr Opin Ophthalmol · 2017Review
- Corneal Endothelial Cell Loss and Morphometric Changes 5 Years after Phacoemulsification with or without CyPass Micro-Stent.
Lass JH, Benetz BA, He J, et al. · Am J Ophthalmol · 2019Multicenter Study, Randomized Controlled Trial
- Endophthalmitis Following XEN Stent Exposure.
Karri B, Gupta C, Mathews D · J Glaucoma · 2018Case Reports
- The Suprachoroidal Route in Glaucoma Surgery.
Gigon A, Shaarawy T · J Curr Glaucoma Pract · 2016Review
Other devices of this type
Also filed under product code OGO.
- iStent Trabecular Micro-Bypass Stent System, iStent inject Trabecular Micro-Bypass System, iStent inject W Trabecular MiGlaukos Corporation · PMA 2022
- iStent inject Trabecular MicroBypass SystemGlaukos Corporation · PMA 2025
- Hydrus MicrostentAlcon Research, LLC · PMA 2025
- iStent inject® W Trabecular Micro-Bypass System Model iS2Glaukos Corporation · PMA 2025
- CyPass System 241-SAlcon Research, Ltd. · PMA 2018
- Glaukos Trabecular Micro Bypass Stent Model GTS100R/LGlaukos Corporation · PMA 2013
- iStent® Trabecular Mjcro-Bypass Stent System, Model GTS100Glaukos Corporation · PMA 2024
- Hydrus MicrosentAlcon Research, LLC · PMA 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.